1. Home
  2. TWIN vs TVGN Comparison

TWIN vs TVGN Comparison

Compare TWIN & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$24.17

Market Cap

320.9M

Sector

Industrials

ML Signal

HOLD

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

N/A

Current Price

$6.57

Market Cap

21.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TWIN
TVGN
Founded
1918
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Blank Checks
Sector
Industrials
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
21.3M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
TWIN
TVGN
Price
$24.17
$6.57
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
76.2K
11.7K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
N/A
EPS
1.76
N/A
Revenue
$340,738,000.00
N/A
Revenue This Year
$10.79
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$13.97
N/A
Revenue Growth
15.45
N/A
52 Week Low
$8.03
$0.14
52 Week High
$25.00
$12.03

Technical Indicators

Market Signals
Indicator
TWIN
TVGN
Relative Strength Index (RSI) 58.77 53.59
Support Level $14.75 $6.33
Resistance Level $24.28 $7.42
Average True Range (ATR) 0.98 0.69
MACD 0.03 0.15
Stochastic Oscillator 71.47 70.40

Price Performance

Historical Comparison
TWIN
TVGN

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: